JUNE 11, 2020
Dyne Therapeutics Appoints Daniel Wilson as Vice President, Head of Intellectual Property
MAY 19, 2020
Dyne Therapeutics Accelerates Programs in Facioscapulohumeral Muscular Dystrophy (FSHD) with Exclusive Licensing of Technologies to Target Genetic Basis of FSHD and Expanded Scientific Advisory Board
